VITRAVENE PRESERVATIVE FREE Drug Patent Profile

« Back to Dashboard

When do Vitravene Preservative Free patents expire, and when can generic versions of Vitravene Preservative Free launch?

Vitravene Preservative Free is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in VITRAVENE PRESERVATIVE FREE is fomivirsen sodium. Additional details are available on the fomivirsen sodium profile page.

Summary for VITRAVENE PRESERVATIVE FREE

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VITRAVENE PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998		DISCN	No	No

International Patents for VITRAVENE PRESERVATIVE FREE

See the table below for patents covering VITRAVENE PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	392081
Austria	A329284
Australia	3423984
Australia	578625

Investment Scenario and Fundamentals Analysis for VITRAVENE PRESERVATIVE FREE

Last updated: April 11, 2026

What is VITRAVENE Preservative-Free?

Vitravene Preservative-Free (generic name: fomivirsen) is an antisense oligonucleotide approved for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS). It was developed by Isis Pharmaceuticals (later acquired by Ionis Pharmaceuticals) and marketed for intravitreal injection. The preservative-free formulation aims to reduce adverse ocular reactions linked to preservatives.

Market Overview

Current Therapeutic Landscape

• Indication: Viral retinitis, specifically CMV retinitis.
• Market size: The global antiviral ophthalmic drugs market was valued at approximately $300 million in 2022, with projections reaching $450 million by 2027.[1]
• Patient Population: Approximately 10-15% of AIDS patients suffer from CMV retinitis.[2]
• Market share: Vitravene once held a niche position; however, its market presence declined as intravitreal injections like ganciclovir and newer agents became standard.

Competitive Position

• Key competitors:
  • Ganciclovir (Viracept)
  • Foscarnet
  • Valganciclovir
  • Emerging biologics and gene therapies
• Vitravene's current market: Limited, largely replaced by cost-effective and more convenient alternatives.

Regulatory Status

• Initial approval: FDA in 1998.
• Current status: Discontinued in 2002, but with preserved stock for investigational uses. No recent approvals or indications.
• Market withdrawal: Due to limited demand, safety concerns, and competition.

Investment Fundamentals

Product Profile

Aspect	Details
Formulation	Preservative-free, intravitreal antisense oligonucleotide
Regulatory approval	FDA-approved (1998); discontinued (2002)
Commercial status	Marketed in the 2000s; no current commercial sales
Manufacturing	Developed by Isis/Esquire Pharmaceuticals (acquired)

Patent and IP Landscape

• Patent status: Original patents expired in the late 2000s.
• Exclusivity: No active patent protections; generic formulations potentially available.
• Data exclusivity: Expired, limiting new proprietary development.

Commercial Viability

• Market decline: Replaced by other antivirals with better efficacy and tolerability.
• Reformulation potential: Limited; monoclonal antibodies and gene therapies are the focus today.
• Resurrecting the product: Requires investment in new clinical trials, with uncertain commercial prospects.

R&D Investment & Risks

• Cost to revive or develop new formulations: High. Clinical trial costs estimated at $50 million–$100 million for Phase I/II studies.
• Likelihood of success: Low, given existing competition and limited unmet needs.
• Intellectual property hurdles: Patent expirations reduce exclusivity, increasing risk of generic competition.

Financial and Strategic Considerations

• Current asset status: The drug is effectively a dormant product; no current sales, and manufacturing assets are likely obsolete.
• Market potential: Minimal without reformulation or new registration.
• Investment risks:
  • Obsolescence due to evolving treatment paradigms.
  • High development costs with uncertain return.
  • Regulatory hurdles for reapproval or new indications.
• Opportunities:
  • Develop a next-generation antisense therapy leveraging technology.
  • Target niche or orphan indications with unmet needs.

Key Takeaways

• Vitravene Preservative-Free has negligible current market value.
• The original product is discontinued; reentry would require significant R&D investment.
• Its competitive landscape is dominated by newer antivirals and biologics.
• Patent expirations and patent cliff reduce barriers to generic entry, pressuring prices.
• Potential value lies in leveraging antisense technology for novel indications rather than reviving the existing drug.

FAQs

1. Is Vitravene Preservative-Free a viable investment today?
No. The drug is discontinued, with minimal current demand. Investment would require significant R&D with uncertain returns.

2. Are there any ongoing clinical trials involving Vitravene?
No. The drug is no longer actively studied or marketed.

3. Could reformulation lead to a new product?
Potentially, but high costs and low likelihood of differentiated benefit limit commercial prospects.

4. What competitive advantages does antisense technology offer?
High specificity and expanding therapeutic applications, especially in genetic and viral diseases.

5. What alternative therapies are replacing Vitravene?
Ganciclovir, foscarnet, valganciclovir, and biologics targeting specific viral proteins.

---

References

1. MarketsandMarkets. (2022). Antiviral drugs market.
2. CDC. (2020). Cytomegalovirus (CMV) and Retinitis in People with HIV.